Vascugen develops regenerative medicines using induced pluripotent stem cell technology to create vasculogenic cells that directly restore blood flow by forming new blood vessels in ischemic tissues. This approach targets critical vascular diseases, such as critical limb ischemia and diabetic retinopathy, where existing treatments are often ineffective.
Funding
$10.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Critical limb ischemia and diabetic retinopathy, severe vascular diseases affecting millions, often lack effective treatments, leading to amputations, vision loss, and increased mortality. Current approaches often fail to adequately restore blood flow to ischemic tissues.
Solution
Vascugen is developing regenerative medicines based on induced pluripotent stem cell (iPSC) technology to create vasculogenic cells that directly form new blood vessels in ischemic tissues, restoring blood flow. Unlike treatments that indirectly stimulate angiogenesis, Vascugen's approach aims for direct vasculogenesis, offering a potential solution for patients with limited or no treatment options. The company's proprietary cell differentiation technology enables consistent and scalable manufacturing of these regenerative medicine products. Vascugen is also exploring partnerships to leverage its technology in tissue engineering, where vasculogenic cells can form microvessels within organoid structures and bio-inks.
Target Audience
The primary target audience includes patients with critical limb ischemia and diabetic retinopathy who have limited or no effective treatment options, as well as researchers and companies in the tissue engineering field.
Features
- Utilizes induced pluripotent stem cell (iPSC) technology for consistent and scalable cell production.
- Proprietary cell differentiation technology to derive unique vasculogenic cells.
- Vasculogenic cells directly form new blood vessels (vasculogenesis) in ischemic tissues.
- Targets critical limb ischemia (CLI) and diabetic retinopathy (DR).
- Potential application in tissue engineering to vascularize organoids and bio-inks.